Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › Youngstown › NPI 1790868982
Hospital

Mercy Health Youngstown LLC

Mercy Health Youngstown LLC was paid $36.60M by Medicaid between Jan 2018 and Dec 2024, across 362 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.

33Billing provider infoMERCY HEALTH YOUNGSTOWN LLC
YOUNGSTOWN, OH 44512
33aNPI1790868982assigned 10/23/2006
28Total paid$36.60M
24GClaims1,036,558
24DCodes billed362
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Ohio

Rank by total paid#33 of 101
Median peer was paid$22.32M
This provider vs. median1.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018100,828$3.17M
2019113,512$3.45M
202093,020$3.43M
2021101,570$3.81M
2022114,373$4.04M
2023291,983$10.60M
2024incomplete221,272$8.10M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 16% 48,617 44,334 $5.99M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 12% 38,571 27,050 $4.44M
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 11% 33,832 32,005 $3.85M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 9.2% 26,274 22,974 $3.37M
74177 Computed tomography, abdomen and pelvis; with contrast material 7.1% 9,894 8,723 $2.61M
70450 Computed tomography, head or brain; without contrast material 5.9% 9,462 8,472 $2.16M
96361 Intravenous infusion, hydration; each additional hour 4.7% 5,564 3,747 $1.74M
G0378 Hospital observation service, per hour 2.4% 9,991 4,592 $886K
74176 Computed tomography, abdomen and pelvis; without contrast material 1.8% 2,739 2,398 $651K
99282 Emergency department visit for the evaluation and management, low to moderate severity 1.7% 6,308 6,043 $608K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 1.4% 2,059 1,145 $497K
71275 Computed tomographic angiography, chest, with contrast material 1.2% 1,746 1,527 $457K
350 more codes
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.1% 3,318 $410K
80053 Comprehensive metabolic panel 1.1% 55,799 $405K
64483 1.0% 728 $382K
95811 <1% 461 $283K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 2,644 $282K
41899 Unlisted procedure, dentoalveolar structures <1% 414 $271K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 695 $265K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,504 $256K
95810 Polysomnography; sleep staging with 4 or more additional parameters <1% 421 $248K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 466 $229K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,999 $195K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 3,629 $192K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 3,120 $182K
80048 Basic metabolic panel (calcium, ionized) <1% 20,729 $174K
83605 <1% 25,455 $160K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 939 $152K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 5,409 $142K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,463 $142K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 6,508 $130K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 545 $121K
76820 <1% 8,023 $117K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 1,227 $114K
76818 <1% 6,470 $112K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 1,726 $107K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 6,745 $103K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 3,616 $102K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,320 $99K
29848 <1% 82 $96K
59025 Fetal non-stress test <1% 562 $95K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 3,222 $93K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 636 $93K
84484 <1% 25,431 $93K
76819 Fetal biophysical profile; without non-stress testing <1% 5,053 $91K
70491 <1% 329 $90K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 73,295 $88K
93975 <1% 864 $82K
93971 <1% 1,121 $77K
72131 <1% 910 $76K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 484 $73K
70496 <1% 313 $70K
71046 Radiologic examination, chest; 2 views <1% 10,400 $69K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 39,356 $67K
86900 <1% 3,165 $66K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 2,433 $65K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 247 $63K
84443 Thyroid stimulating hormone (TSH) <1% 4,205 $62K
97161 <1% 1,203 $62K
78815 Positron emission tomography (PET) for limited area imaging <1% 191 $61K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 542 $60K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 29,366 $57K
95800 <1% 203 $57K
93970 <1% 442 $56K
71045 Radiologic examination, chest; single view <1% 13,597 $55K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 3,532 $54K
76770 <1% 362 $50K
99201 <1% 835 $49K
76536 <1% 421 $47K
76821 <1% 2,215 $46K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 584 $46K
97113 <1% 569 $45K
71250 <1% 590 $41K
47563 <1% 19 $39K
62323 <1% 138 $39K
76830 Ultrasound, transvaginal <1% 776 $38K
J1756 Injection, iron sucrose, 1 mg <1% 1,248 $37K
36415 Collection of venous blood by venipuncture <1% 29,474 $36K
94060 <1% 230 $34K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 16,650 $33K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 1,819 $33K
97165 <1% 662 $32K
72125 Computed tomography, cervical spine; without contrast material <1% 2,222 $32K
81001 <1% 36,598 $31K
70551 Magnetic resonance imaging, brain; without contrast material <1% 219 $30K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 49 $28K
86850 <1% 2,586 $28K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 122 $27K
82728 <1% 1,796 $27K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 70 $27K
69436 Tympanostomy (requiring insertion of ventilating tube), general anesthesia <1% 16 $26K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 473 $26K
71271 <1% 159 $25K
J2790 Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) <1% 377 $25K
85027 <1% 5,828 $25K
96375 Therapeutic injection; each additional sequential IV push <1% 23,948 $23K
96415 <1% 121 $23K
99213 Doctor's office visit, returning patient (routine) <1% 238 $21K
84439 <1% 1,999 $20K
80061 Lipid panel <1% 1,914 $20K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 8,304 $20K
83880 <1% 4,857 $20K
82607 <1% 1,524 $19K
83036 Hemoglobin; glycosylated (A1C) <1% 2,241 $18K
70486 <1% 408 $17K
83735 <1% 7,058 $17K
72141 <1% 112 $17K
94729 <1% 225 $16K
12001 <1% 105 $16K
83690 <1% 21,831 $16K
94726 <1% 221 $16K
76801 <1% 784 $15K
87088 <1% 6,185 $15K
96367 <1% 393 $15K
64493 <1% 28 $14K
80320 <1% 1,024 $14K
74018 <1% 466 $14K
73030 <1% 1,028 $13K
96376 <1% 3,616 $13K
77067 Screening mammography, bilateral, including computer-aided detection <1% 306 $13K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,151 $12K
73502 <1% 643 $12K
93017 <1% 136 $11K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 1,371 $11K
C1713 Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) <1% 487 $11K
73630 <1% 1,056 $11K
00170 Anesthesia for intraoral procedures, including biopsy <1% 507 $11K
86901 <1% 3,125 $11K
84702 <1% 2,363 $10K
83540 <1% 1,178 $10K
G0382 Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) <1% 114 $10K
73130 <1% 849 $10K
90714 <1% 657 $10K
73700 <1% 99 $10K
70498 <1% 270 $10K
86140 <1% 1,122 $9K
84112 <1% 179 $9K
86592 <1% 629 $9K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 1,408 $9K
82570 <1% 1,761 $8K
81002 <1% 35,666 $8K
84550 <1% 1,568 $8K
73562 <1% 872 $8K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 78 $8K
72128 <1% 250 $8K
86803 <1% 551 $8K
87040 <1% 2,695 $8K
83550 <1% 1,120 $8K
85610 <1% 4,351 $8K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 320 $7K
93226 <1% 43 $7K
72100 <1% 544 $7K
82746 <1% 1,380 $7K
82962 <1% 5,336 $7K
80076 <1% 1,242 $7K
86038 <1% 415 $7K
83970 <1% 313 $7K
87340 <1% 499 $6K
73221 <1% 25 $6K
87081 <1% 519 $6K
73610 <1% 798 $6K
36430 <1% 54 $6K
76813 <1% 183 $6K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 435 $6K
P9016 Red blood cells, leukocytes reduced, each unit <1% 44 $5K
84156 <1% 1,479 $5K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 934 $5K
72110 <1% 81 $5K
86376 <1% 402 $5K
97535 Self-care/home management training, each 15 minutes <1% 189 $4K
73110 <1% 535 $4K
86039 <1% 233 $4K
64721 <1% 14 $4K
74420 <1% 37 $4K
77063 Screening digital breast tomosynthesis, bilateral <1% 213 $4K
85378 <1% 1,258 $4K
93225 <1% 43 $4K
73560 <1% 292 $3K
J2791 Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu <1% 55 $3K
97014 <1% 104 $3K
74178 <1% 18 $3K
86800 <1% 241 $3K
84134 <1% 238 $3K
81003 <1% 5,919 $3K
73590 <1% 363 $3K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 1,003 $3K
93246 <1% 37 $3K
84100 <1% 899 $3K
84481 <1% 230 $3K
83615 <1% 677 $3K
87210 <1% 748 $3K
82731 <1% 81 $3K
86703 <1% 95 $3K
85379 <1% 1,732 $3K
84520 <1% 264 $2K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 42 $2K
10060 <1% 15 $2K
84630 <1% 176 $2K
J0500 Injection, dicyclomine hcl, up to 20 mg <1% 252 $2K
85652 <1% 844 $2K
85730 <1% 1,318 $2K
A9609 Fludeoxyglucose f18 up to 15 millicuries <1% 13 $2K
76870 <1% 76 $2K
94664 <1% 1,135 $2K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 331 $2K
99203 Doctor's office visit, new patient (routine) <1% 29 $2K
82565 <1% 308 $2K
C1776 Joint device (implantable) <1% 232 $2K
84425 <1% 174 $2K
80143 <1% 1,553 $2K
86923 <1% 60 $2K
84703 <1% 1,155 $2K
12002 <1% 14 $2K
82550 <1% 1,007 $2K
J3490 Unclassified drugs <1% 98 $2K
82784 <1% 173 $2K
87077 <1% 978 $2K
86762 <1% 115 $1K
82248 <1% 1,287 $1K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 2,488 $1K
J2270 Injection, morphine sulfate, up to 10 mg <1% 3,564 $1K
85651 <1% 364 $1K
J1170 Injection, hydromorphone, up to 4 mg <1% 2,483 $1K
82043 <1% 278 $1K
J1650 Injection, enoxaparin sodium, 10 mg <1% 2,064 $1K
86787 <1% 53 $1K
87070 <1% 814 $1K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 20,109 $1K
82805 <1% 69 $1K
82947 <1% 455 $1K
73564 <1% 45 $1K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 2,589 $1K
85014 <1% 563 $1K
92567 <1% 33 $968.33
86308 <1% 323 $936.08
64447 <1% 14 $935.43
82077 <1% 632 $905.87
82525 <1% 69 $901.74
80179 <1% 1,534 $877.48
84145 <1% 254 $870.74
80074 <1% 100 $848.89
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,092 $824.11
87634 <1% 311 $815.30
82044 <1% 118 $813.95
85384 <1% 270 $797.25
J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg <1% 84 $730.77
00790 <1% 249 $714.38
86481 <1% 13 $701.28
87205 <1% 702 $700.85
86147 <1% 46 $665.48
85018 <1% 559 $618.73
86317 <1% 26 $590.03
86706 <1% 31 $588.27
J1642 Injection, heparin sodium, (heparin lock flush), per 10 units <1% 1,433 $586.67
87186 <1% 404 $578.09
C1889 Implantable/insertable device, not otherwise classified <1% 37 $568.33
J0690 Injection, cefazolin sodium, 500 mg <1% 4,995 $562.66
90715 <1% 27 $528.80
81025 <1% 555 $520.79
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 19,267 $506.54
J3475 Injection, magnesium sulfate, per 500 mg <1% 933 $468.72
73090 <1% 78 $447.06
J3010 Injection, fentanyl citrate, 0.1 mg <1% 9,230 $414.21
83020 <1% 41 $411.62
J2360 Injection, orphenadrine citrate, up to 60 mg <1% 832 $391.16
J2704 Injection, propofol, 10 mg <1% 11,730 $386.70
01810 <1% 763 $378.34
84590 <1% 51 $376.25
82533 <1% 31 $369.10
73552 <1% 45 $365.49
85460 <1% 33 $347.07
86431 <1% 16 $338.69
84403 <1% 34 $331.90
86403 <1% 160 $306.67
82010 <1% 573 $303.56
82553 <1% 19 $299.64
82800 <1% 491 $295.37
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 4,246 $286.30
88342 <1% 304 $276.81
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 6,112 $269.18
71101 <1% 14 $229.17
J0780 Injection, prochlorperazine, up to 10 mg <1% 929 $223.63
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 728 $213.92
82140 <1% 72 $212.98
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 18,344 $200.55
73521 <1% 16 $200.52
83516 <1% 24 $194.25
72170 <1% 30 $187.97
87449 <1% 27 $174.07
J3370 Injection, vancomycin hcl, 500 mg <1% 626 $171.75
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 425 $170.92
80164 <1% 17 $166.70
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 2,121 $161.24
J2060 Injection, lorazepam, 2 mg <1% 689 $153.18
84146 <1% 13 $142.10
A9579 Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml <1% 761 $128.99
J1030 Injection, methylprednisolone acetate, 40 mg <1% 2,493 $119.43
82150 <1% 55 $111.15
87075 <1% 156 $104.30
85045 <1% 29 $91.71
J0171 Injection, adrenalin, epinephrine, 0.1 mg <1% 370 $71.21
73080 <1% 13 $65.59
J0360 Injection, hydralazine hcl, up to 20 mg <1% 141 $65.48
J2470 Injection, pantoprazole sodium, 40 mg <1% 222 $64.21
J7030 Infusion, normal saline solution , 1000 cc <1% 830 $60.46
J2550 Injection, promethazine hcl, up to 50 mg <1% 222 $58.23
J2175 Injection, meperidine hydrochloride, per 100 mg <1% 31 $57.78
84436 <1% 29 $48.32
00813 <1% 173 $47.60
J1644 Injection, heparin sodium, per 1000 units <1% 104 $41.62
J1836 Injection, metronidazole, 10 mg <1% 135 $39.55
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 5,565 $36.53
J3480 Injection, potassium chloride, per 2 meq <1% 511 $35.59
J1953 Injection, levetiracetam, 10 mg <1% 16 $35.07
J2795 Injection, ropivacaine hydrochloride, 1 mg <1% 583 $31.55
C1769 Guide wire <1% 200 $27.40
88304 <1% 910 $22.01
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 27 $20.52
84132 <1% 48 $19.06
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 26 $17.95
73060 <1% 15 $15.56
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 42 $15.28
J1010 Injection, methylprednisolone acetate, 1 mg <1% 330 $11.13
J1940 Injection, furosemide, up to 20 mg <1% 169 $10.95
J7050 Infusion, normal saline solution, 250 cc <1% 416 $9.77
J1596 Injection, glycopyrrolate, 0.1 mg <1% 393 $9.29
J1171 Injection, hydromorphone, 0.1 mg <1% 185 $7.57
J0688 Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg <1% 19 $6.36
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 1,004 $5.36
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 95 $2.35
J1790 Injection, droperidol, up to 5 mg <1% 49 $2.25
J2371 Injection, phenylephrine hydrochloride, 20 micrograms <1% 361 $1.90
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg <1% 36 $1.76
J1920 Injection, labetalol hydrochloride, 5 mg <1% 31 $0.86
Q0244 Injection, casirivimab and imdevimab, 1200 mg <1% 52 $0.37
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 910 $0.25
00811 0% 86 $0.00
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 0% 154 $0.00
00731 0% 455 $0.00
H1000 Prenatal care, at-risk assessment 0% 154 $0.00
A9577 Injection, gadobenate dimeglumine (multihance), per ml 0% 44 $0.00
A4565 Slings 0% 71 $0.00
J1020 Injection, methylprednisolone acetate, 20 mg 0% 79 $0.00
C1758 Catheter, ureteral 0% 25 $0.00
A9537 Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries 0% 31 $0.00
00840 0% 67 $0.00
00812 0% 75 $0.00
00910 0% 18 $0.00
J7120 Ringers lactate infusion, up to 1000 cc 0% 19 $0.00
64484 0% 86 $0.00
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose 0% 101 $0.00
J1921 Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg 0% 14 $0.00
88311 0% 241 $0.00
96368 0% 36 $0.00
J2785 Injection, regadenoson, 0.1 mg 0% 14 $0.00
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 0% 13 $0.00
64494 0% 28 $0.00
C9399 Unclassified drugs or biologicals 0% 107 $0.00
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 0% 13 $0.00
G0379 Direct admission of patient for hospital observation care 0% 52 $0.00
J0330 Injection, succinylcholine chloride, up to 20 mg 0% 17 $0.00
87807 0% 26 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Same official

Other billing entities under RALSTON, KIMBERLY

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.